Anti-VEGF Drugs Dynamics: Relevance for Clinical Practice.
Daniele VerittiValentina SaraoGianluca GorniPaolo LanzettaPublished in: Pharmaceutics (2022)
Fixed q8 ranibizumab, q8 bevacizumab, q12 aflibercept, or q10 brolucizumab regimens may produce adequate intraocular VEGF inhibition.